40 Cases In Aredia, Zometa MDL Survive Dismissal Bid

Law360, New York (March 5, 2010, 3:11 PM EST) -- A federal judge has denied a bid by Novartis Pharmaceuticals Corp. to toss 40 cases in multidistrict litigation that alleges the company failed to adequately warn that its bone cancer drugs Aredia and Zometa could cause jawbones to deteriorate.

Judge Todd J. Campbell of the U.S. District Court for the Middle District of Tennessee denied Novartis' summary judgment motion on Wednesday. The 40 cases were brought under Florida law, and Novartis argued a state statute required the judge to throw out the cases.

The suits represent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.